Supervisor Database Search

Guidance for ICAT Supervisors

The ICAT Supervisor list is reviewed annually by the partner universities and updated online in March/April each year.

You can read about the ICAT supervisor selection process and eligibility criteria below:

Terms of reference/guide to supervising ICAT Fellows.

You can read the terms of reference for supervisors actively supervising ICAT Fellows below:

Supervisor Database

Search for supervisors below. You can filter your search using the options and select multiple fields by holding CTRL (Cmd on Mac) + clicking multiple options in a list.

Full NameProfessor Matthew Griffin

School of Medicine

University of Galway

Webpage:curamdevices.ie

Email hidden; Javascript is required.

Research Fields
  • infectious disease and the immune system
  • cell and developmental biology/regenerative medicine
  • clinical trials
Postgrad Medical Specialties
  • Medicine
  • Surgery
  • Pathology
Medical Subspecialties
  • Endocrinology
  • Gastroenterology
  • Haematology
  • Infectious diseases
  • Immunology
  • Nephrology
  • Pharmacology
  • Rheumatology
  • Vascular Medicine
My Work

My research has focussed for the past 20 years on basic and translational studies of the immune system and inflammation - particularly their contributions to the pathophysiology of kidney disease and transplantation (e.g. Kidney Int. 2007,71:619-628; J Am Soc Nephrol, 21: 1987-1997,2010; J Am Soc Nephrol, 23:194-203,2012). Since returning to Ireland in 2008, I have directed these interests to the field of regenerative medicine and allogeneic cell therapies with an emphasis on the immunomodulatory properties of mesenchymal stromal cells/MSC (e.g. Am J Physiol Renal Physiol 307:F1412-26,2016; Stem Cells, 31:2033-41,2014; Immunol Cell Biol, 96: 536–548,2018; Frontiers Immunol, Nov 20;9:2666,2018).

With colleagues and collaborators in REMEDI and at several leading centres in Europe and the US, my group has recently been closely involved in translating allogeneic cell therapies to the clinic through regulator-approved early phase clinical trials (see www.visicort.eu and www.nephstrom.eu) as well as biomarker and immune profiling studies (e.g. Immunol Cell Biol, 96: 675-784,2018; Frontiers Immunol, Dec 6;9:2845,2018; Clin Chem Lab Med, ePub, Sept 15,2018). We have strong expertise in flow cytometry, primary immune cell isolation and culture, immunoassays, pre-clinical models and histology/immunohistochemistry. We also have extensive experience in patient-oriented research.

Scroll to Top